15 Participants Needed

ELISIO™-HX Dialyzer for Kidney Failure

JO
RZ
Overseen ByRebecca Zickert
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Nipro Medical Corporation
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial evaluates the safety and effectiveness of a new artificial kidney, the ELISIO™-HX dialyzer, for individuals with kidney failure. The main goals are to determine if it maintains stable protein levels and enhances the body's ability to remove certain waste products. Individuals who regularly undergo hemodialysis and have a stable treatment routine may qualify for this study. The results could inform future dialysis options. As an unphased trial, this study allows patients to contribute to innovative research that may enhance future kidney treatments.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

What prior data suggests that the ELISIO™-HX Dialyzer is safe for kidney failure patients?

A previous study found the ELISIO™-HX Dialyzer to be safe for patients. This device functions like an artificial kidney, cleaning waste from the blood for individuals with kidney failure. Research has shown it does not significantly alter albumin levels, which is beneficial. Albumin, a protein in the blood, helps maintain fluid balance in the bloodstream.

The ELISIO™-HX is recognized for its precise filtering ability, effectively removing waste while keeping important proteins like albumin at safe levels. This is crucial for individuals at higher risk, such as those who are malnourished or frail.

Overall, early findings suggest the ELISIO™-HX is well-tolerated, with no major safety concerns reported.12345

Why are researchers excited about this trial?

The ELISIO™-HX Dialyzer is unique because it introduces a novel medium cut-off technology designed to function as an artificial kidney for people with renal failure. Unlike traditional dialyzers, which may struggle to filter out larger toxins, the ELISIO™-HX aims to remove a broader range of molecules, potentially leading to better overall purification of the blood. Researchers are excited about this advancement because it could mean improved outcomes and quality of life for patients undergoing dialysis, offering a more comprehensive filtration process than current options.

What evidence suggests that the ELISIO™-HX dialyzer is effective for kidney failure?

Studies have shown that the ELISIO™-HX dialyzer, used by participants in this trial, effectively removes certain harmful substances from the blood in patients with kidney failure. Research indicates that this dialyzer efficiently removes specific medium-sized molecules called lambda free light chains, which can cause harm if they accumulate in the blood. One study found that both the ELISIO™-HX and a similar dialyzer effectively removed small and medium-sized molecules, with no major differences in performance. Additionally, the ELISIO™-HX is designed to protect important proteins like albumin, which are necessary for health, while still cleaning the blood effectively.12345

Who Is on the Research Team?

KD

Kiranjit Dhillon, MD, MPH

Principal Investigator

Davita Norfolk Dialysis Center

Are You a Good Fit for This Trial?

This trial is for adults aged 22 and older with end-stage renal disease on hemodialysis, or those 18-21 weighing at least 40 kg. Participants must be clinically stable, have used the ELISIO-H dialyzer for 3 months prior to enrollment, expected to live at least another year, and able to consent.

Inclusion Criteria

I have signed a consent form to participate.
I am 22 or older with end-stage kidney disease on dialysis, or 18-21 and weigh at least 40 kg.
My health has been stable for the last 30 days according to my doctor.
See 5 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive treatment using the ELISIO™-HX dialyzer to evaluate safety and performance

8-12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • ELISIO™-HX
Trial Overview The safety and efficacy of the ELISIO™-HX Dialyzer are being tested. The study aims to show that it doesn't affect pre-dialysis albumin levels (safety) and improves clearance of certain molecules from the blood (efficacy).
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: ELISIO™-HX DialyzerExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Nipro Medical Corporation

Lead Sponsor

Bright Research Partners

Industry Sponsor

Trials
18
Recruited
2,700+

Citations

Premarket Clinical Safety Assessment of the ELISIO™-HXHemodialysis therapy with the ELISIO-H dialyzer for at least 3 months immediately prior to study enrollment and expected to survive for the next 12 months.
ELISIO™-HX Dialyzer for Kidney FailureThe study aims to show that it doesn't affect pre-dialysis albumin levels (safety) and improves clearance of certain molecules from the blood (efficacy). How Is ...
Comparative Analysis of the ELISIO-HX and Xevonta-Hi ...Both dialyzers demonstrated excellent clearance of small and middle molecules, with no significant differences in efficacy. Albumin and total protein losses ...
ELISIO™ HXThe sharp cut-off feature of Elisio HX distinguishes this membrane for patients vulnerable to loss of albumin such as patients with malnutrition, frailty,.
CLINICAL SAFETY ASSESSMENT OF ELISIO™-HX ...This study focuses on assessing the safety and effectiveness of the ELISIO™-HX, a type of hemodialyzer used in dialysis treatments.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security